featured
Dabrafenib and Trametinib vs Dabrafenib and Placebo for Val600 BRAF-Mutant Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dabrafenib and Trametinib Versus Dabrafenib and Placebo for Val600 BRAF-Mutant Melanoma: A Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial
Lancet 2015 May 30;[EPub Ahead of Print], GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, C Garbe, T Jouary, A Hauschild, JJ Grob, V Chiarion-Sileni, C Lebbe, M Mandalà, M Millward, A Arance, I Bondarenko, JB Haanen, J Hansson, J Utikal, V Ferraresi, N Kovalenko, P Mohr, V Probachai, D Schadendorf, P Nathan, C Robert, A Ribas, DJ DeMarini, JG Irani, S Swann, JJ Legos, F Jin, B Mookerjee, K FlahertyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.